GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer

Journal article

Peer reviewed

K.S. Tewari, B.J. Monk, A. Oaknin, S. Lheureux, F. Zagouri, D. Rischin, K. Hasegawa, Y.M. Kim, R. Pereira, A. Sadozye, …

Gynecologic oncology, Vol.159, pp.160-161

10/2020

Metrics

4 Record Views

Title: GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer
Creators: K.S. Tewari - University of California, Irvine
B.J. Monk - Creighton University
A. Oaknin - Hebron University
S. Lheureux - Princess Margaret Cancer Centre
F. Zagouri - National and Kapodistrian University of Athens
D. Rischin - Peter MacCallum Cancer Centre
K. Hasegawa - Saitama Medical University
Y.M. Kim - University of Ulsan
R. Pereira - CASA
A. Sadozye - NHS Greater Glasgow and Clyde
P.H. Wang - Taipei Veterans General Hospital
A. Lisyanskaya - St. Petersburg State Budgetary institution of Healthcare, City Clinical Oncological Dispensary, St Petersburg, Russian Federation
V. Samouëlian - Centre Hospitalier de l’Université de Montréal
H.S. Kim - Seoul National University
M. Zambrano - Regeneron
S. Yi - Regeneron
J. Li - Regeneron
M. Feng - Regeneron
M. Mathias - Regeneron
M.G. Fury - Regeneron
I. Lowy - Regeneron
I. Vergote - Leuven Cancer Institute, Leuven, Belgium
Publication Details: Gynecologic oncology, Vol.159, pp.160-161
Publisher: Elsevier Inc
Identifiers: 991005969162502656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article